NeOnc reports updated NEO100 data: 24% radiographic remission, 44% PFS-6 in recurrent IDH1-mutant astrocytoma

NEONC TECHNOLOGIES HOLDINGS, INC.

6 of 25 patients (24%) achieved radiographic remission vs <8% historical salvage therapies.
44% achieved 6-month progression-free survival (PFS-6), exceeding historical 21-31% benchmarks.
9 of 25 patients (36%) remain alive ≥18 months post NEO100 initiation; no significant toxicity seen.
All patients had recurrent WHO Grade III/IV IDH1-mutant astrocytoma; data from Phase 1/2a and compassionate use.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.